Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Liver Cirrhosis

Free Subscription 22.12.2025 1 BMC Gastroenterol 1 Clin Res Hepatol Gastroenterol 1 Dig Dis Sci 1 Digestion 8 Hepatology 3 J Hepatol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. YI Y, Chen Y, Luo Y
   Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database.
   BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04499.
   PubMed        
   
   

   
   Clin Res Hepatol Gastroenterol

2. TIROTTA D, Lena C, Torre M, Muratori P, et al
   Hematologic Focal Hepatic Lesions in the Absence of Liver Cirrhosis: Consider Lymphoma and Myeloma.
   Clin Res Hepatol Gastroenterol. 2025 Dec 16:102749.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

3. DODGE JL, Kim B
   Branched-Chain Amino Acid Supplementation in Patients with Cirrhosis: Boon, Bust, or Bull?
   Dig Dis Sci. 2025 Dec 16. doi: 10.1007/s10620-025-09614.
   PubMed        
   
   

   
   Digestion

4. HASSNINE AA, Elsayed AM, Higazi MM, Saied M, et al
   Impact of Direct Acting Antivirals on the hemodynamics of the portal circulation in cirrhotic patients infected with hepatitis C virus.
   Digestion. 2025 Dec 15:1-15. doi: 10.1159/000549612.
   PubMed         Abstract available
   
   

   
   Hepatology

5. KORATALA A, Argaiz ER
   Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
   Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
   PubMed        
   
   
6. PREMKUMAR M, Kajal K
   Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
   Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
   PubMed        
   
   
7. KHAN S
   PSC and HCC: Age and cirrhosis draw the line on risk.
   Hepatology. 2026;83:1.
   PubMed        
   
   
8. CHAGANTI J, Zeng G, Patil A, Lockart I, et al
   Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
   Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
   PubMed         Abstract available
   
   
9. HAZARI Y, Habbouche L, Garcia Lopez VA, Urra H, et al
   Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.
   Hepatology. 2026;83:75-93.
   PubMed         Abstract available
   
   
10. PANAGIOTOPOULOS N, Wolfson T, Harris DT, Batakis D, et al
    Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:127-141.
    PubMed         Abstract available
    
    
11. SU R, Tao X, Yan L, Liu Y, et al
    Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
    PubMed         Abstract available
    
    
12. HARRISON SA, Dubourg J, Knott M, Colca J, et al
    Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:169-177.
    PubMed         Abstract available
    
    

    
    J Hepatol

13. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
14. XU D, Zhang Z, Zhu Z, Wei W, et al
    Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.
    J Hepatol. 2026;84:165-180.
    PubMed         Abstract available
    
    
15. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.